WELCOME!
to IMGT/mAb-DB
THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM®
IMGT
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF


IMGT/mAb-DB ID 793
INN faricimab
INN Number 10563
INN Prop. List 118 (2017)
INN Rec. List 80 (2018)
Common name RO6867461, RG7716, faricimab-svoa
Proprietary name VABYSMO™
Species Homo sapiens
Humanized
IMGT receptor type IG
Format (legend)
Receptor identification IgG1 - kappa - lambda with half-IG VL-CH1/VH-CK crossover
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB 10563
IMGT/3Dstructure-DB
Specificity target name and species VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens, Humanized]
ANGPT2 (angiopoietin 2, Ang2) [Homo sapiens, Humanized]
bispecific [Homo sapiens, Humanized]
Development Technology CrossMAb technology
Origin clone species Mus musculus Homo sapiens
Origin clone name ;

Company Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
Expression system
Application Therapeutic
Clinical domain Ophthalmology
Mechanism of action
Clinical indication Age-related macular degeneration (AMD), neovascular (wet)
Development status Phase M
Regulatory agency status and year
  • FDA approval January 28, 2022

Company Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
Expression system CHO (Chinese Hamster Ovary) cells
Application Therapeutic
Clinical domain Immunology; Ophthalmology
Mechanism of action
Clinical indication Diabetic macular edema
Development status Phase M
Regulatory agency status and year
  • FDA approval January 28, 2022

Clinical trials 9 studies found, 1 recruiting
Authority decisions
External links
Biosimilars
    Format legend:

    © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
    European Commission umontpellier CNRS